Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Latest Information Update: 21 Oct 2024
At a glance
- Drugs S 65487 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Servier
Most Recent Events
- 16 Oct 2024 Status changed from completed to discontinued (The study was prematurely terminated on 14th March 2023 for strategic considerations due to the limited efficacy seen with this treatment in monotherapy. This decision was not based on any safety concerns).
- 21 Mar 2024 Status changed from active, no longer recruiting to completed.
- 27 Feb 2023 Planned End Date changed from 1 Mar 2024 to 10 Jul 2023.